Purilogics to Present at 13th Annual Bioprocessing Summit
Purilogics, a swiftly growing start-up noted for its novel affinity membrane chromatography technology, development, and commercialization, will be presenting their most up-to-date research on their rapid antibody and mRNA purification technologies at the 13th Annual Bioprocessing Summit.
Poster V-9
Recent events, such as the FDA’s Emergency Use Authorization of two novel SARS-CoV-2 vaccines, have led to an expeditious rise in the interest in the development of mRNA-based medicines. Thus, developing innovative solutions to the challenges presented by mRNA drug discovery and industrial production has equally received attention in the bioprocessing and biopharmaceutical industries.
In his presentation titled “Rapid mRNA Purification Using Novel Membrane Absorbers”, Associate Director of Research Graham Temples, PhD., will compare Purilogics’ novel, high throughput mRNA affinity membrane to current commercially available mRNA affinity resin products. Specifically, the effects of flowrate and mRNA size on binding capacity and recovery in these competing products will be highlighted.
Poster V-10
Current antibody purification technologies, magnetic and resin bead products, are needlessly time consuming and often result in unsatisfactory purity levels after processing. Purilogics Co-founder and Vice President Jinxiang Zhou, PhD., in his presentation titled “Getting More with Less: Membrane-Based Antibody Chromatography and You”, will speak on Purilogics’ most recent developments in their Protein A affinity membrane products (Purexa™ PrA) and how this tool will increase productivity by simplifying workflow, reducing the time needed to purify antibody, and improving both throughput and purity levels.
Check out the full Purilogics product lineup here
